Fangzhou Inc. and Bristol Myers Squibb China Join Forces on a Strategic Alliance to Advance Internet Healthcare
SHANGHAI, Dec. 19, 2024 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a pioneer in Internet healthcare solutions, announced a strategic alliance with Bristol Myers Squibb ("BMS") China on December 16th. The partnership was officially formalized with the signing of a collaboration agreement by Dr. Xie Fangmin, founder, chairman, and CEO...
Caliway to Present CBL-514 Phase 2b Study Results for Subcutaneous Fat Reduction at IMCAS 2025 in Paris
The findings from the CBL-0204 Phase 2b clinical trial have been selected for presentation at IMCAS, the premier global congress in aesthetic medicine. The data will be highlighted in both the 2025 focus session on advances in fat reduction therapies and further detailed in the Non-surgical Body Contouring session through an...
Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection
LOS ANGELES, Dec. 19, 2024 /PRNewswire/ -- Pharus Diagnostics LLC. (PharusDx), an innovator in non-invasive diagnostic tests, today announced a significant step forward in the fight against pancreatic cancer. The company is announcing availability of its OncoSweep™ Pancreas Spotlight, a liquid biopsy screening test that aids in the detection of Pancreatic Ductal...
Clarity expands its pipeline with a novel optimised FAP-targeted radiopharmaceutical
Highlights Clarity has developed a proprietary fibroblast activation protein (FAP)-targeted radiopharmaceutical product that can be used with the perfect pairing of copper isotopes for the diagnosis and treatment of cancer. The product, termed SAR-bisFAP, has shown strong tumour targeting, retention and pharmacokinetic data to date in pre-clinical models. FAP is expressed...
Boryung Announces Winners of the 3rd Humans In Space Challenge
Paving the Way as a Global Leader in Space Healthcare - Introducing of a new funding model to support space experiments and strengthen research in space healthcare - Hosted the final round of the Humans In Space Challenge at the 75th International Astronautical Congress SEOUL, South Korea, Dec. 18, 2024 /PRNewswire/ --...
DNAnexus Recognized by Frost & Sullivan for Ability to Integrate and Synchronize Diverse Clinical and Multi-omics Data
Leading cloud-based enterprise platform for precision health data empowers biopharma companies with actionable insights to accelerate drug discovery and development SAN ANTONIO, Dec. 18, 2024 /PRNewswire/ -- Frost & Sullivan researched the bioinformatics-based drug discovery and development industry, and based on its analysis results, today recognized DNAnexus, provider of the leading enterprise platform for precision health data, with the 2024 Global Enabling Technology...
Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model
In a head-to-head diet-induced obese (DIO) mouse study, ASC47 low dose combination 1 (ASC47, 3 mg/kg, subcutaneous (SQ), once every four weeks plus semaglutide, 30 nmol/kg, SQ, once daily), demonstrated superior weight loss compared to semaglutide monotherapy (30 nmol/kg, SQ, once daily), showing an average total body weight reduction of 36.2% compared to 23.1%, a 56.7% greater reduction...
Juncell Therapeutics Opens State-of-the-Art Facility for TIL Production
SHANGHAI, Dec. 18, 2024 /PRNewswire/ -- Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech focused on innovative IL-2-independent Tumor-Infiltrating Lymphocyte (TIL) therapies, announced the grand opening of its state-of-the-art TIL manufacturing facility located at Anting International Medical Industry Park in Jiading District, Shanghai, China. This facility has the largest capacity and was constructed in compliance with the...
Apollo Care Secures Growth Equity Investment from Flexpoint Ford to Accelerate Patient Access and Commercial Solutions Initiatives
Strategic investment from Flexpoint Ford to drive Apollo Care's growth initiatives Proceeds will be used to expand Apollo Care's innovation pipeline, enhance existing technology, and scale operations Flexpoint Ford's Jonathan Oka and Elliot Lauzen join Apollo Care's Board of Directors CHICAGO, Dec. 18, 2024 /PRNewswire/ -- Apollo Care, a rapidly growing provider of patient access and commercial solutions...
Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head...
BEIJING and BRIDGEWATER, N.J., Dec. 18, 2024 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087.SH), is pleased to announce that the Food and Drug Administration (" FDA ") has cleared the Investigational New Drug (IND) application for GZR18 Injection to conduct a phase 2 clinical trial, a head-to-head...
